Inhibiteurs de la cyclooxygénase 2 : Questions médicales fréquentes
Nom anglais: Cyclooxygenase 2 Inhibitors
Descriptor UI:D052246
Tree Number:D27.505.954.329.030.500.500
Termes MeSH sélectionnés :
Geographic Atrophy
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Inhibiteurs de la cyclooxygénase 2 : Questions médicales les plus fréquentes",
"headline": "Inhibiteurs de la cyclooxygénase 2 : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Inhibiteurs de la cyclooxygénase 2 : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-07-12",
"dateModified": "2025-04-08",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Inhibiteurs de la cyclooxygénase 2"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Inhibiteurs des cyclooxygénases",
"url": "https://questionsmedicales.fr/mesh/D016861",
"about": {
"@type": "MedicalCondition",
"name": "Inhibiteurs des cyclooxygénases",
"code": {
"@type": "MedicalCode",
"code": "D016861",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.954.329.030.500"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Inhibiteurs de la cyclooxygénase 2",
"alternateName": "Cyclooxygenase 2 Inhibitors",
"code": {
"@type": "MedicalCode",
"code": "D052246",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Afshin Zarghi",
"url": "https://questionsmedicales.fr/author/Afshin%20Zarghi",
"affiliation": {
"@type": "Organization",
"name": "Department of Pharmaceutical Chemistry, School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran."
}
},
{
"@type": "Person",
"name": "Rui Wang",
"url": "https://questionsmedicales.fr/author/Rui%20Wang",
"affiliation": {
"@type": "Organization",
"name": "Department of Gastroenterology, West China Hospital, Sichuan University, Chengdu, China."
}
},
{
"@type": "Person",
"name": "Mahsa Azami Movahed",
"url": "https://questionsmedicales.fr/author/Mahsa%20Azami%20Movahed",
"affiliation": {
"@type": "Organization",
"name": "Department of Pharmaceutical Chemistry, School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran."
}
},
{
"@type": "Person",
"name": "Mohammad Mahboubi-Rabbani",
"url": "https://questionsmedicales.fr/author/Mohammad%20Mahboubi-Rabbani",
"affiliation": {
"@type": "Organization",
"name": "Islamic Azad University, Tehran Department of Medicinal Chemistry Tehran Iran."
}
},
{
"@type": "Person",
"name": "Ying Wang",
"url": "https://questionsmedicales.fr/author/Ying%20Wang",
"affiliation": {
"@type": "Organization",
"name": "College of Pharmacy, Pusan National University, Busan 46241, Republic of Korea."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "The Role of Inflammation in Age-Related Macular Degeneration-Therapeutic Landscapes in Geographic Atrophy.",
"datePublished": "2023-08-18",
"url": "https://questionsmedicales.fr/article/37626902",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3390/cells12162092"
}
},
{
"@type": "ScholarlyArticle",
"name": "Emerging treatments for geographic atrophy and the impact on clinical management of age-related macular degeneration.",
"datePublished": "2024-06-04",
"url": "https://questionsmedicales.fr/article/39477789",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1080/08164622.2024.2361752"
}
},
{
"@type": "ScholarlyArticle",
"name": "Exploring patient acceptability of emerging intravitreal therapies for geographic atrophy: A mixed-methods study.",
"datePublished": "2023-05-11",
"url": "https://questionsmedicales.fr/article/37170013",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1038/s41433-023-02571-3"
}
},
{
"@type": "ScholarlyArticle",
"name": "Deep Learning to Predict Geographic Atrophy Area and Growth Rate from Multimodal Imaging.",
"datePublished": "2022-08-28",
"url": "https://questionsmedicales.fr/article/36038116",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.oret.2022.08.018"
}
},
{
"@type": "ScholarlyArticle",
"name": "Explainable artificial intelligence model for the detection of geographic atrophy using colour retinal photographs.",
"datePublished": "2023-12-06",
"url": "https://questionsmedicales.fr/article/38057106",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1136/bmjophth-2023-001411"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Actions chimiques et utilisations",
"item": "https://questionsmedicales.fr/mesh/D020164"
},
{
"@type": "ListItem",
"position": 3,
"name": "Actions pharmacologiques",
"item": "https://questionsmedicales.fr/mesh/D020228"
},
{
"@type": "ListItem",
"position": 4,
"name": "Utilisations thérapeutiques",
"item": "https://questionsmedicales.fr/mesh/D045506"
},
{
"@type": "ListItem",
"position": 5,
"name": "Antirhumatismaux",
"item": "https://questionsmedicales.fr/mesh/D018501"
},
{
"@type": "ListItem",
"position": 6,
"name": "Anti-inflammatoires non stéroïdiens",
"item": "https://questionsmedicales.fr/mesh/D000894"
},
{
"@type": "ListItem",
"position": 7,
"name": "Inhibiteurs des cyclooxygénases",
"item": "https://questionsmedicales.fr/mesh/D016861"
},
{
"@type": "ListItem",
"position": 8,
"name": "Inhibiteurs de la cyclooxygénase 2",
"item": "https://questionsmedicales.fr/mesh/D052246"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Inhibiteurs de la cyclooxygénase 2 - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Inhibiteurs de la cyclooxygénase 2",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-17",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Inhibiteurs de la cyclooxygénase 2",
"description": "Comment diagnostiquer une inflammation nécessitant des COX-2 ?\nQuels tests sont utilisés pour évaluer l'efficacité des COX-2 ?\nLes COX-2 sont-ils prescrits pour toutes les douleurs ?\nComment différencier les douleurs inflammatoires des autres ?\nQuels signes cliniques indiquent l'utilisation des COX-2 ?",
"url": "https://questionsmedicales.fr/mesh/D052246?mesh_terms=Geographic+Atrophy&page=2#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Inhibiteurs de la cyclooxygénase 2",
"description": "Quels symptômes traitent les inhibiteurs de COX-2 ?\nLes COX-2 soulagent-ils la fièvre ?\nQuels effets secondaires peuvent survenir avec les COX-2 ?\nLes COX-2 affectent-ils l'humeur ?\nPeut-on ressentir des douleurs abdominales avec les COX-2 ?",
"url": "https://questionsmedicales.fr/mesh/D052246?mesh_terms=Geographic+Atrophy&page=2#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Inhibiteurs de la cyclooxygénase 2",
"description": "Comment prévenir les effets secondaires des COX-2 ?\nY a-t-il des mesures préventives avant de commencer les COX-2 ?\nLes patients à risque doivent-ils éviter les COX-2 ?\nComment surveiller l'efficacité des COX-2 ?\nLes changements de mode de vie aident-ils avec les COX-2 ?",
"url": "https://questionsmedicales.fr/mesh/D052246?mesh_terms=Geographic+Atrophy&page=2#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Inhibiteurs de la cyclooxygénase 2",
"description": "Quels médicaments sont des inhibiteurs de COX-2 ?\nComment les COX-2 sont-ils administrés ?\nLes COX-2 peuvent-ils être combinés avec d'autres médicaments ?\nQuelle est la durée du traitement avec les COX-2 ?\nLes COX-2 sont-ils disponibles sans ordonnance ?",
"url": "https://questionsmedicales.fr/mesh/D052246?mesh_terms=Geographic+Atrophy&page=2#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Inhibiteurs de la cyclooxygénase 2",
"description": "Quelles complications peuvent survenir avec les COX-2 ?\nLes COX-2 augmentent-ils le risque d'accidents vasculaires ?\nComment gérer les complications des COX-2 ?\nLes complications sont-elles fréquentes avec les COX-2 ?\nQuels signes indiquent une complication avec les COX-2 ?",
"url": "https://questionsmedicales.fr/mesh/D052246?mesh_terms=Geographic+Atrophy&page=2#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Inhibiteurs de la cyclooxygénase 2",
"description": "Quels facteurs augmentent le risque d'effets secondaires des COX-2 ?\nL'âge influence-t-il le risque avec les COX-2 ?\nLes femmes enceintes peuvent-elles utiliser des COX-2 ?\nLe tabagisme affecte-t-il l'utilisation des COX-2 ?\nLes antécédents familiaux influencent-ils le risque ?",
"url": "https://questionsmedicales.fr/mesh/D052246?mesh_terms=Geographic+Atrophy&page=2#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer une inflammation nécessitant des COX-2 ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un diagnostic repose sur l'examen clinique et des tests d'imagerie pour évaluer l'inflammation."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour évaluer l'efficacité des COX-2 ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des échelles de douleur et des tests fonctionnels peuvent être utilisés pour évaluer l'efficacité."
}
},
{
"@type": "Question",
"name": "Les COX-2 sont-ils prescrits pour toutes les douleurs ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Non, ils sont généralement prescrits pour des douleurs inflammatoires spécifiques comme l'arthrite."
}
},
{
"@type": "Question",
"name": "Comment différencier les douleurs inflammatoires des autres ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les douleurs inflammatoires sont souvent accompagnées de raideur matinale et d'enflure."
}
},
{
"@type": "Question",
"name": "Quels signes cliniques indiquent l'utilisation des COX-2 ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des signes comme l'enflure, la chaleur et la douleur persistante peuvent indiquer leur utilisation."
}
},
{
"@type": "Question",
"name": "Quels symptômes traitent les inhibiteurs de COX-2 ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Ils traitent principalement la douleur et l'inflammation associées à des conditions comme l'arthrite."
}
},
{
"@type": "Question",
"name": "Les COX-2 soulagent-ils la fièvre ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Non, les inhibiteurs de COX-2 ne sont pas principalement utilisés pour traiter la fièvre."
}
},
{
"@type": "Question",
"name": "Quels effets secondaires peuvent survenir avec les COX-2 ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les effets secondaires incluent des troubles gastro-intestinaux, des maux de tête et des vertiges."
}
},
{
"@type": "Question",
"name": "Les COX-2 affectent-ils l'humeur ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Ils ne sont pas connus pour affecter directement l'humeur, mais la douleur chronique peut le faire."
}
},
{
"@type": "Question",
"name": "Peut-on ressentir des douleurs abdominales avec les COX-2 ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des douleurs abdominales peuvent survenir en raison d'effets secondaires gastro-intestinaux."
}
},
{
"@type": "Question",
"name": "Comment prévenir les effets secondaires des COX-2 ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Pour prévenir les effets secondaires, il est conseillé de les prendre avec de la nourriture et de suivre les doses prescrites."
}
},
{
"@type": "Question",
"name": "Y a-t-il des mesures préventives avant de commencer les COX-2 ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, un bilan de santé et une évaluation des antécédents médicaux sont recommandés."
}
},
{
"@type": "Question",
"name": "Les patients à risque doivent-ils éviter les COX-2 ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les patients avec des antécédents de problèmes cardiaques doivent consulter un médecin avant de les utiliser."
}
},
{
"@type": "Question",
"name": "Comment surveiller l'efficacité des COX-2 ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "La surveillance peut inclure des évaluations régulières de la douleur et des tests de laboratoire."
}
},
{
"@type": "Question",
"name": "Les changements de mode de vie aident-ils avec les COX-2 ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, un mode de vie sain peut améliorer l'efficacité des traitements anti-inflammatoires."
}
},
{
"@type": "Question",
"name": "Quels médicaments sont des inhibiteurs de COX-2 ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des exemples incluent le célécoxib et le rofécoxib, utilisés pour traiter l'inflammation."
}
},
{
"@type": "Question",
"name": "Comment les COX-2 sont-ils administrés ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Ils sont généralement administrés par voie orale sous forme de comprimés ou de capsules."
}
},
{
"@type": "Question",
"name": "Les COX-2 peuvent-ils être combinés avec d'autres médicaments ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, mais il est important de consulter un médecin pour éviter les interactions médicamenteuses."
}
},
{
"@type": "Question",
"name": "Quelle est la durée du traitement avec les COX-2 ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "La durée dépend de la condition traitée, mais elle doit être déterminée par un médecin."
}
},
{
"@type": "Question",
"name": "Les COX-2 sont-ils disponibles sans ordonnance ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Non, les inhibiteurs de COX-2 nécessitent généralement une prescription médicale."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec les COX-2 ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des complications peuvent inclure des problèmes gastro-intestinaux, des troubles cardiaques et des réactions allergiques."
}
},
{
"@type": "Question",
"name": "Les COX-2 augmentent-ils le risque d'accidents vasculaires ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certains inhibiteurs de COX-2 peuvent augmenter le risque d'accidents vasculaires cérébraux."
}
},
{
"@type": "Question",
"name": "Comment gérer les complications des COX-2 ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "La gestion des complications nécessite une consultation médicale et un ajustement du traitement."
}
},
{
"@type": "Question",
"name": "Les complications sont-elles fréquentes avec les COX-2 ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications ne sont pas fréquentes, mais elles peuvent survenir chez certains patients à risque."
}
},
{
"@type": "Question",
"name": "Quels signes indiquent une complication avec les COX-2 ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des signes comme des douleurs thoraciques, des saignements gastro-intestinaux ou des éruptions cutanées doivent alerter."
}
},
{
"@type": "Question",
"name": "Quels facteurs augmentent le risque d'effets secondaires des COX-2 ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les antécédents de maladies cardiaques, d'ulcères ou d'allergies augmentent le risque."
}
},
{
"@type": "Question",
"name": "L'âge influence-t-il le risque avec les COX-2 ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les personnes âgées peuvent avoir un risque accru d'effets secondaires et de complications."
}
},
{
"@type": "Question",
"name": "Les femmes enceintes peuvent-elles utiliser des COX-2 ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'utilisation des COX-2 pendant la grossesse doit être évitée sauf si prescrite par un médecin."
}
},
{
"@type": "Question",
"name": "Le tabagisme affecte-t-il l'utilisation des COX-2 ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le tabagisme peut augmenter le risque de complications gastro-intestinales avec les COX-2."
}
},
{
"@type": "Question",
"name": "Les antécédents familiaux influencent-ils le risque ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des antécédents familiaux de maladies cardiaques peuvent augmenter le risque d'effets secondaires."
}
}
]
}
]
}
Age-related macular degeneration (AMD) is the leading cause of vision loss and visual impairment in people over 50 years of age. In the current therapeutic landscape, intravitreal anti-vascular endoth...
Age-related macular degeneration (AMD) is a leading cause of vision impairment in people over 50 years of age and has a great impact on quality of life as it affects central vision. Although there hav...
The acceptability of emerging intravitreal therapies for patients with Geographic Atrophy (GA) is currently unknown. This study therefore aimed to investigate the extent to which regular intravitreal ...
Thirty UK-based individuals with GA secondary to age-related macular degeneration (AMD), recruited from two London-based hospitals, were interviewed in April-October 2021 regarding acceptability of ne...
Twenty participants (67%) were female, and median (interquartile range (IQR)) age was 83 (78, 87) years. 37% of participants had foveal centre-involving GA, and better eye median (IQR) logMAR visual a...
Our study suggests a majority of participants would be positive about intravitreal treatment for GA, in spite of potential burdens....
To develop deep learning models for annualized geographic atrophy (GA) growth rate prediction using fundus autofluorescence (FAF) images and spectral-domain OCT volumes from baseline visits, which can...
This retrospective analysis estimated GA growth rate as the slope of a linear fit on all available measurements of lesion area over a 2-year period. Three multitask deep learning models-FAF-only, OCT-...
Patients were from prospective and observational lampalizumab clinical trials....
The 3 models were trained on the development data set, tested on the holdout set, and further evaluated on the independent test sets. Baseline FAF images and OCT volumes from study eyes of patients wi...
Model performance was evaluated using squared Pearson correlation coefficient (r...
On the holdout data set, r...
We show the feasibility of using baseline FAF images and OCT volumes to predict individual GA area and growth rates using a multitask deep learning approach. The deep learning-based growth rate predic...
Proprietary or commercial disclosure may be found after the references....
To develop and validate an explainable artificial intelligence (AI) model for detecting geographic atrophy (GA) via colour retinal photographs....
We conducted a prospective study where colour fundus images were collected from healthy individuals and patients with retinal diseases using an automated imaging system. All images were categorised in...
A total of 540 colour retinal photographs were collected. Data was divided such that 300 images from each class trained the AI model, 120 for validation and 120 for performance testing. In distinguish...
Our explainable AI model exhibits excellent performance in detecting GA using colour retinal images. With its high sensitivity, specificity and overall diagnostic accuracy, the AI model stands as a po...
To present a deep learning algorithm for segmentation of geographic atrophy (GA) using en face swept-source OCT (SS-OCT) images that is accurate and reproducible for the assessment of GA growth over t...
Retrospective review of images obtained as part of a prospective natural history study....
Patients with GA (n = 90), patients with early or intermediate age-related macular degeneration (n = 32), and healthy controls (n = 16)....
An automated algorithm using scan volume data to generate 3 image inputs characterizing the main OCT features of GA-hypertransmission in subretinal pigment epithelium (sub-RPE) slab, regions of RPE lo...
The GA area, enlargement rate of GA area, square root of GA area, and square root of the enlargement rate of GA area measurements were calculated using the automated algorithm and compared with ground...
There were no significant differences in the GA areas, enlargement rates of GA area, square roots of GA area, and square roots of the enlargement rates of GA area between the graders and the automated...
When compared with manual methods, this proposed deep learning-based automated algorithm for GA segmentation using en face SS-OCT images was able to accurately delineate GA and produce reproducible me...
Geographic atrophy (GA) is a progressive and irreversible retinal disease with no comprehensive recommendations for diagnosis or monitoring. We used a Delphi approach to determine consensus in key are...
To investigate the therapeutic effect of intravitreal pegcetacoplan on the inhibition of photoreceptor (PR) loss and thinning in geographic atrophy (GA) on conventional spectral-domain OCT (SD-OCT) im...
Post hoc analysis of a prospective, multicenter, randomized, sham (SM)-controlled, masked phase II trial investigating the safety and efficacy of pegcetacoplan for the treatment of GA because of age-r...
Study eyes of 246 patients, randomized 1:1:1 to monthly (AM), bimonthly (AEOM), and SM treatment....
We performed fully automated, deep learning-based segmentation of retinal pigment epithelium (RPE) loss and PR thickness on SD-OCT volumes acquired at baseline and months 2, 6, and 12. The difference ...
Square-root transformed PR loss area in μm or mm, PR thickness in μm, and PR loss/RPE loss ratio....
A total of 31 556 B-scans of 644 SD-OCT volumes of 161 study eyes (AM 52, AEOM 54, SM 56) were evaluated from baseline to month 12. Comparison of the mean change in PR loss area revealed statistically...
Distinct and reliable quantification of PR loss using deep learning-based algorithms offers an essential tool to evaluate therapeutic efficacy in slowing disease progression. Photoreceptor loss and th...
To determine whether the outer retinal layer (ORL) thickness around geographic atrophy (GA) could serve as a clinical biomarker to predict the annual enlargement rate (ER) of GA....
Retrospective analysis of a prospective, observational case series....
Eyes with GA were imaged with a swept-source OCT 6 × 6 mm scan pattern. GA lesions were measured from customized en face OCT images and the annual ERs were calculated. The ORL was defined and segmente...
A total of 38 eyes from 27 participants were included. The same eyes were used for the choriocapillaris (CC) flow deficit (FD) analysis and the RPE to the Bruch membrane (RPE-BM) distance measurements...
ORL thickness showed a significant negative correlation with annual GA growth, but also showed a significant correlation with the RPE-BM distances, suggesting that they were dependently correlated wit...
To examine associations between the topographic distribution of geographic atrophy (GA) and vision-related quality of life (VRQoL)....
This study included 237 eyes from 161 participants in the Age-Related Eye Disease Study (AREDS). GA lesions were manually delineated with color fundus photographs obtained by the AREDS Research Group ...
The average area of atrophy in the better and worse eye was 3.43mm...
In patients with GA, greater area of atrophy in the central 1-mm-diameter zone of the better eye was independently associated with lower VRQoL, while total area of atrophy in the better or worse eye w...